Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 70518-4241

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 70518-4241). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This is a description of Lurasidone HCI, a medication available in 20 mg tablets. The quantity in each packet is 30 tablets. The source NDC is 43598-0351-30, and the manufacturer is Dr. Reddy's located in Shreveport, LA. The medication should be stored at 20-25°C (58-77°F), with excursions permitted to 15-30°C (59-86°F). It is important to keep this medication out of the reach of children. For instructions on usage, refer to the package insert. This medication has been repackaged by RemedyRepack Inc. located in Indiana, PA.*

FDA Label Image

Figure1 (Figure1)

This text summarizes the impact of different drugs on the pharmacokinetics of Lurasidone. It includes details on the fold change in Cmax and AUC with interacting drugs such as Ketoconazole (a strong CYP3A4 inhibitor), Diltiazem (a moderate CYP3A4 inhibitor), Rifampin (a strong CYP3A4 inducer), and Lithium. The text provides an insight into how these drugs affect the pharmacokinetics of Lurasidone when taken together.*

FDA Label Image

Figure2 (Figure2)

This text appears to be a table showing the pharmacokinetic fold change and 90% confidence interval for various drugs when interacting with other substances. It includes information on P-glycoprotein substrates (e.g., Digoxin), CYP3A4 substrates (e.g., Midazolam), and Oral Contraceptives (e.g., Ethinyl Estradiol). The table likely provides data on the change relative to the interactive drug alone for these compounds.*

FDA Label Image

Figure3 (Figure3)

Not available.*

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.